Richard Johnson founded Upperton Pharma Solutions in August 1999, and continues to play a key role in the management and strategic development of the company. With over 30 years of experience in the pharmaceutical, biotechnology and drug delivery fields, Dr Johnson previously held senior management positions at Andaris Limited (Vectura) and Delta Biotechnology (now Albumedix, Nottingham, UK). Dr Johnson holds an
honours degree in Biology from University of York (UK) and a PhD from the University of Warwick (UK) and has a proven track record in successfully developing innovative pharmaceutical products from early feasibility studies through to commercial products.
Richard Johnson discusses the advantages of nasal delivery and why there is growing interest in this route of administration, as well as considering some of the challenges that may arise during the development of nasal formulations for use in the clinic, and the regulatory and testing requirements associated with them.